Hepatitis C virus (HCV) is a positive-strand RNA virus that belongs to the Flaviviridae family. Among seven distinct genotypes, genotype 1 is the most frequent in the United States and in Western Europe ([@bib11]). 30% of infected individuals spontaneously clear the virus, whereas the others develop chronic infection. Morbidity associated with chronic hepatitis C mainly results from the development of liver fibrosis and cirrhosis, with complications such as hepatocellular carcinoma and liver failure. Treatment of chronic hepatitis C with pegylated IFN-α and ribavirin (PEG-IFN-α/RBV) results in a sustained virological response (SVR) in ∼50% of patients infected with genotype 1/4, and in 70--90% of those infected with genotype 2/3 ([@bib26]). Although new antiviral agents such as telaprevir ([@bib27]) and boceprevir ([@bib2]; [@bib16]) improve cure rates, treatment remains long, burdened with adverse effects, costly, with limited availability to many areas, and may lead to the emergence of resistance.

Recent genome-wide association studies (GWAS) showed that single nucleotide polymorphisms (SNPs) nearby *IL28B* (mainly *rs12979860*) are strongly associated with spontaneous ([@bib20]) and treatment-induced clearance of HCV infection ([@bib6]; [@bib23]; [@bib24]; [@bib20]). *IL28B* encodes type III IFN-λ3, a cytokine which has antiviral properties both in vitro and in vivo ([@bib9]; [@bib22]; [@bib14]; [@bib21]; [@bib1]; [@bib8]). Numerous investigators confirmed the importance of *IL28B* SNPs in the natural course and treatment of HCV infection ([@bib12]; [@bib19]; [@bib13]; [@bib10]).

It remains unknown whether *rs12979860* exerts biological effects or whether it is in linkage disequilibrium (LD) with other functional polymorphisms. The expression of IL28B was reported to be lower in whole blood or PBMCs from individuals carrying the mutant alleles than those carrying the WT alleles ([@bib23]; [@bib24]), but these observations were not unequivocally confirmed in liver biopsies from patients with chronic hepatitis C ([@bib7]; [@bib25]; [@bib5]). The functional effect was proposed to result from *rs8103142*, a nonsynonymous SNP in LD with *rs12979860*, which induces a K-to-R substitution at amino acid position 70 of IL28B ([@bib6]). However, this SNP was not among the most significantly associated with clearance in GWAS. Furthermore, K70 and R70 protein variants did not induce different levels of IFN-stimulated gene (ISG) expression or different inhibition of HCV replication in Huh-7.5 cells ([@bib25]). Other investigators performed gene mapping but failed to detect new SNPs with a stronger genetic effect ([@bib4]) or with a clear functional mechanism.

RESULTS AND DISCUSSION
======================

By sequencing the putative regulatory region upstream of *IL28B*, we identified a T deletion (previously described as *rs67272382* NT_011109.16:g.12007372delT) adjacent to a T-to-G substitution (previously described as *rs74597329* NT_011109.16:g.12007373T\>G), located at position 39739154 and 39739155 in chromosome 19 (Genome Build 37.1). The presence of the TT/-G substitution, as well as the previously known *rs12979860*, was explored in a cohort of 540 Caucasian patients with chronic HCV infection and in 93 patients with spontaneous HCV clearance ([Table S1](http://www.jem.org/cgi/content/full/jem.20130012/DC1){#supp1}). The *rs12979860* and TT/-G polymorphisms were in strong LD (R^2^ = 0.91) and both had a minor allele frequency of 0.38. Despite such strong correlation, individuals who were discordant at both SNPs allowed us to explore which of the two SNPs is most strongly associated with the outcome and therefore more likely to be the functional variant.

We assessed whether *IL28B* polymorphisms were associated with response to PEG-IFN-α/RBV therapy among chronically infected patients. When considering all viral genotypes together, both polymorphisms were associated with response to treatment ([Fig. 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, and [Table S2](http://www.jem.org/cgi/content/full/jem.20130012/DC1){#supp2}). The strongest and most significant association was found for TT/-G (OR = 0.38, 95% CI 0.28--0.51, P = 2.51^−10^), compared with *rs12979860* (0.46, 95% CI 0.35--0.62, P = 1.52^−7^). TT/-G still provided the strongest and most significant association in a multivariate model, after adjustment for age, sex, HCV RNA level, fibrosis stage, and viral genotype (OR = 0.27, 95% Cl 0.17--0.45, P = 2.70^−7^), compared with *rs12979860* (OR = 0.37, 95% CI 0.23--0.59, P = 2.47^−5^). When both polymorphisms were included in the same model, the mutant -G allele of TT/-G was still associated with reduced clearance, whereas the mutant T allele of *rs12979860* was associated with increased clearance (OR\>1, [Table 2](#tbl2){ref-type="table"}). TT/-G had a better ability than *rs12979860* to discriminate SVR rates (P = 0.04, [Fig. 1 A](#fig1){ref-type="fig"}). The SVR proportion was 0.80, 0.55, and 0.41 for patients carrying the TT/TT, TT/-G, and -G/-G genotypes, compared with 0.77, 0.56, and 0.45 for those carrying *rs12979860* CC, CT, and TT genotypes (P = 0.02, [Fig. 1 B](#fig1){ref-type="fig"}). Altogether, this confirms that TT/-G is a better marker for HCV clearance than *rs12979860* and that the mutant -G allele, but not the *rs12979860* mutant T allele, is associated with reduced clearance. The *rs12979860* mutant T allele likely represents a proxy for the effect of the mutant -G allele.

![**TT/-G is a better predictor of response to treatment than *rs12979860*.** (A) Association of the mutant -G allele of TT/-G and the mutant T allele of *rs12979860* with HCV clearance. *\** , P = 0.04. Error bars represent 95% confidence level. (B) TT/-G versus *rs12979860* in SVR to treatment in chronically HCV-infected patients. \*\*, P = 0.02. Analyses were performed in 540 Caucasian patients from the Swiss Hepatitis C Cohort Study. Numbers of patients in each group are described in [Table 1](#tbl1){ref-type="table"}. All genotypes were validated by an independent laboratory as described in the materials and methods. Odds ratios are for an additive model, accounting for the effect of one or two copies of the mutant allele. Multivariate models are adjusted for age and sex, HCV RNA level, fibrosis stage, and viral genotype. P-values were calculated using the integrated discrimination improvement (IDI) test.](JEM_20130012R_Fig1){#fig1}

###### 

Association of *IL28B* polymorphisms with HCV clearance in chronic hepatitis C

  Response to treatment                                                         Genotype   T     NR    SVR   Prop. SVR[b](#tblfn2){ref-type="table-fn"}   Univariate models   Multivariate models[d](#tblfn4){ref-type="table-fn"}                       
  ----------------------------------------------------------------------------- ---------- ----- ----- ----- -------------------------------------------- ------------------- ------------------------------------------------------ ------------------- ----------
  **All viral genotypes[a](#tblfn1){ref-type="table-fn"} (*n* = 540)**                                                                                                                                                                                   
  TT/-G                                                                         TT/TT            37    152   0.80                                                                                                                                        
                                                                                TT/-G            131   161   0.55                                                                                                                                        
                                                                                -G/-G            35    24    0.41                                         0.38 (0.28--0.51)   2.51^−10^                                              0.27 (0.17--0.45)   2.70^−7^
  *rs12979860*                                                                  CC               43    146   0.77                                                                                                                                        
                                                                                CT               126   163   0.56                                                                                                                                        
                                                                                TT               34    28    0.45                                         0.46 (0.35--0.62)   1.52^−7^                                               0.37 (0.23--0.59)   2.47^−5^
  **Viral genotype 1 and 4^a^** **(*n* = 288)**                                                                                                                                                                                                          
  TT/-G                                                                         TT/TT      82    22    60    0.73                                                                                                                                        
                                                                                TT/-G      174   112   62    0.36                                                                                                                                        
                                                                                -G/-G      32    26    6     0.19                                         0.25 (0.16--0.40)   4.61^−9^                                               0.16 (0.08--0.33)   2.75^−7^
  *rs12979860*                                                                  CC         80    24    56    0.70                                                                                                                                        
                                                                                CT         173   109   64    0.37                                                                                                                                        
                                                                                TT         35    27    8     0.23                                         0.31 (0.20--0.49)   2.24^−7^                                               0.22 (0.11--0.41)   3.46^−6^
  **Viral genotype 2 and 3[c](#tblfn3){ref-type="table-fn"}** **(*n* = 252)**                                                                                                                                                                            
  TT/-G                                                                         TT/TT            15    92    0.86                                                                                                                                        
                                                                                TT/-G            19    99    0.84                                                                                                                                        
                                                                                -G/-G            9     18    0.67                                         0.36 (0.15--0.86)   2.13^−2^                                               1.33 (0.22--7.94)   7.57^−1^
  *rs12979860*                                                                  CC               19    90    0.83                                                                                                                                        
                                                                                CT               17    99    0.85                                                                                                                                        
                                                                                TT               7     20    0.74                                         0.54 (0.21--1.38)   2.01^−1^                                               1.48 (0.26--8.53)   6.59^−1^
  **Spontaneous clearance (*n* = 633)[a](#tblfn1){ref-type="table-fn"}**                                                                                                                                                                                 
  TT/-G                                                                         TT/TT            189   63                                                                                                                                                
                                                                                TT/-G            292   29                                                                                                                                                
                                                                                -G/-G            59    1                                                  0.28 (0.18--0.43)   8.68^−9^                                               0.30 (0.19--0.47)   1.54^−7^
  *rs12979860*                                                                  CC               189   62                                                                                                                                                
                                                                                CT               289   30                                                                                                                                                
                                                                                TT               62    1                                                  0.29 (0.19--0.45)   1.66^−8^                                               0.31 (0.20--0.49)   3.64^−7^

CRI, chronic infection; SC, spontaneous clearance; NR, nonresponse to treatment; OR, odds ratio; CI, confidence interval; Prop, proportion.

Odd ratios and p-values are for an additive model, accounting for increased effect of one or two copies of the mutant allele.

Data indicate the proportion of patients with SVR for indicated host and viral genotypes.

Odd ratios and p-values are for a recessive model, comparing the presence of two copies versus zero or one copies of the mutant allele.

Multivariate models are adjusted for age and sex (spontaneous clearance), as well as HCV RNA level, fibrosis stage, and, whenever appropriate, viral genotype (response to treatment). Multivariate models include a smaller number of patients, due to missing covariates in some patients (*n* = 360 for all genotypes, *n* = 195 for genotypes 1 and 4, and *n* = 165 for genotypes 2 and 3). However, the results of univariate analyses restricted to the subset of individuals with all covariates were concordant with those of the whole group.

###### 

Independent contribution of *rs12979860* and TT/-G to HCV clearance

  Response to treatment                                        Polymorphisms included in the same model             
  ------------------------------------------------------------ ---------------------------------------------------- ----------
  **All viral genotypes; *n* = 540**                                                                                
  Polymorphisms by pairs                                                                                            
  TT/-G                                                        0.12 (0.03--0.40)                                    5.94^−4^
  *rs12979860*                                                 3.41 (1.01--11.4)[a](#tblfn5){ref-type="table-fn"}   4.77^−2^
  **Viral genotypes 1 and 4, *n* = 288**                                                                            
  Polymorphisms by pairs                                                                                            
  TT/-G                                                        0.16 (0.05--0.55)                                    3.60^−3^
  *rs12979860*                                                 1.61 (0.48--5.40)[a](#tblfn5){ref-type="table-fn"}   4.44^−1^
  **Spontaneous clearance[b](#tblfn6){ref-type="table-fn"}**                                                        
  Polymorphisms by pairs                                                                                            
  TT/-G                                                        0.42 (0.14--1.30)                                    1.31^−1^
  *rs12979860*                                                 0.66 (0.22--1.99)                                    4.59^−1^

Both TT/-G and *rs12978960* were introduced in the same logistic regression model. OR, odds ratio; CI, confidence interval. OR represent the additive effect of the mutant allele (-G for TT/-G and T for *rs12979860*).

When TT/-G was entered into the model, the direction of the association of the T allele of *rs12979860* was reversed (OR \> 1).

93 individuals with spontaneous HCV clearance were compared to 540 patients with chronic infection

Similar observations were found after stratification by viral genotypes ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). In patients infected with HCV genotype 1/4, the strongest and most significant association was also found for TT/-G either in the univariate (OR = 0.25, 95% CI 0.16--0.40, P = 4.61^−9^ vs. OR = 0.31, 95% CI 0.20--0.49, P = 2.24^−7^ for *rs12979860*) or in the multivariate models (OR = 0.16, 95% CI 0.08--0.33, P = 2.75^−7^ vs. OR = 0.22, 95% CI 0.11--0.41, P = 3.46^−6^ for *rs12979860*). In patients infected with HCV genotype 2/3, TT/-G was the only SNP associated with response to treatment, but only in a recessive model (OR = 0.36, 95% CI 0.15--0.86, P = 2.13^−2^). Finally, TT/-G was also a better marker of spontaneous clearance ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, P = 8.68^−9^), compared with *rs12979860* (P = 1.66^−8^).

Because TT/-G is a better marker of HCV clearance, we speculated that it might correlate with *IL28B* mRNA expression. To address this issue, we measured *IL28B* mRNA expression in PBMCs from individuals carrying different allelic combinations of *rs12979860* and TT/-G that were stimulated with the dsRNA analogue poly(I:C) ([Fig. 2, A and C](#fig2){ref-type="fig"}). Among individuals WT for *rs12979860*, PBMCs from those carrying one or two copies of the mutant allele -G of TT/-G had lower expression of IL28B mRNA compared with those from TT/-G WT individuals (P \< 0.001). In contrast, among individuals WT for TT/-G, those carrying one or two copies of the mutant allele T of *rs12979860* had similar expression of IL28B mRNA than those WT for *rs12979860*. Finally, among individuals carrying one or two copies of the mutant allele T of *rs12979860*, those carrying one or two copies of the mutant allele -G of TT/-G had lower expression of IL28B mRNA compared with those from TT/-G WT individuals (P = 0.007). The pattern of IL28B expression after stimulation was similar among patients with cured hepatitis C (SVR) and those with chronic infection (nonresponse) according to TT/-G, suggesting that the viremic state does not significantly influence acute response to stimulation in vitro ([Fig. 2 C](#fig2){ref-type="fig"}). Altogether, these data demonstrate that IL28B mRNA expression is driven by the presence of one or two mutant alleles of TT/-G but not by *rs12979860*. Because *IL28B* has a strong homology with *IL28A* due to ancestral gene duplication events, we sequenced previously cloned amplicons to unambiguously confirm that they were part of *IL28B* but not *IL28A* (unpublished data).

![**Expression of IL28B and IP-10 mRNA relies on TT/-G but not *rs12979860* polymorphism.** PBMCs from healthy and HCV-infected individuals were stimulated with poly(I:C) for 4 h (black) and 8 h (dark gray). The mRNA expression of IL28B and IP-10 was measured by RT-PCR. Results grouped according to different allelic combinations of the mutant T allele of *rs12979860* and the mutant -G allele of TT/-G are shown in A (IL28B) and B (IP-10). Individual results are shown in C. As a control, TNF expression was measured after stimulation with LPS (C, bottom). AU, arbitrary units; mut, mutant allele; NA, not assessed; NR, nonresponse to treatment. For each individual, stimulation was performed in triplicate. P-values are calculated by linear regression. *\** , P \< 0.001; \*\*, P = 0.007; ^+^, P \< 0.001; ^++^, P = 0.006. N stands for the number of individuals. Error bars represent standard error. \#, unstimulated cells.](JEM_20130012R_Fig2){#fig2}

Although the number of individuals carrying discrepant genotypes was low, the reduction in IL28B mRNA expression among samples from individuals carrying the mutant TT/-G allele was strongly significant. Recently, [@bib18] also identified TT/-G as a better predictor of response to treatment than *rs12979860* among African Americans, whereas it did not improve this prediction among Caucasians. This can be explained by the lower level of LD between the two polymorphisms among African Americans (R^2^ = 0.71) compared with Caucasian (R^2^ = 0.92). Thus, the high proportion of *rs12979860* and TT/-G discrepant individuals in the African American population would allow further validation of the functional role of TT/-G on IL28B mRNA expression.

Infection with HCV activates the endogenous IFN system, which leads to the induction of ISGs and contributes to viral clearance. Pretreatment plasmatic levels of ISGs, such as IFN-γ--inducible protein 10 (IP-10), are predictors of HCV clearance. Because the induction of IP-10 is thought to rely on both type I and type III IFNs, we analyzed IP-10 mRNA expression in PBMCs stimulated with poly(I:C) for 8 h ([Fig. 2, B and C](#fig2){ref-type="fig"}). As for IL28B, IP-10 expression was lower among individuals carrying the mutant allele of TT/-G but not in those carrying the mutant allele of *rs12979860* ([Fig. 2 B](#fig2){ref-type="fig"}), indicating that Il28B expression could be a determinant for the induction of some ISGs. These observations suggest a strong link between the mutant -G allele of TT/-G, reduced expression of IL28B, lower induction of ISGs, and HCV treatment failure. However, the mechanisms by which IL28B TT/-G genotypes are related to ISG induction and clinical phenotypes remain to be elucidated. As a control, TNF mRNA expression after LPS stimulation was not influenced by both polymorphisms ([Fig. 2 C](#fig2){ref-type="fig"}).

Genetic polymorphisms can influence gene function through different mechanisms. For instance, they can disrupt or create DNA regulatory elements affecting gene expression. In addition, SNPs can influence the ability of DNA sequences to undergo methylation, thereby influencing gene expression. Both *rs12979860* and TT/-G are located within a CpG island which has been identified on the UCSC human genome draft by the Miklem and Hillier method. As assessed by bisulfite sequencing, TT/-G polymorphism was found to promote the methylation of a cytosine residue which is unmethylated in WT DNA sequences ([Fig. 3](#fig3){ref-type="fig"}). Further studies are needed to determine the relationship between TT/-G and surrounding CpG methylation and IL28B and/or ISG expression.

![**The TT/-G creates a methylation site in the CpG region.** The TT/-G substitution is associated with the methylation of the adjacent cytosine residue (indicated by arrow). As opposed to methylated cytosine residues (indicated by asterisks), unmethylated cytosine residues, C, are replaced by thymine, T, after bisulfite treatment and subsequent PCR amplification.](JEM_20130012_Fig3){#fig3}

[@bib18] showed that TT/-G introduces a frame shift in the DNA sequence, which transiently induces mRNA expression of an IFN analogue (IFNL4) in human hepatocytes stimulated with poly(I:C). Only patients carrying the mutant allele -G express IFNL4. The authors suggest that this protein could be a direct marker of HCV treatment failure and a new target for therapeutic intervention, raising major interest in the medical community. Nevertheless, issues regarding the molecular functions of IFNL4 remain to be clarified, such as the inability of recombinant IFNL4 to directly induce the Jak--STAT pathway in HepG2 cells, unless by transfection of an IFNL4 construct. Furthermore, the low secretion level of IFNL4 together with the lack of demonstration of its effective binding to the IFNL receptor and/or another specific receptor raises questions about its physiological function.

Using a large European cohort, we identified a new TT/-G polymorphism nearby *IL28B* that influences both IL28B and IP-10 mRNA expression and improves HCV clearance prediction in patients infected with HCV viral genotype 1/4 or 2/3. Because IL28B has antiviral properties, reduced IL28B expression may impair individual ability to clear HCV by itself. Whether this phenomenon is further influenced by another protein remains to be demonstrated. TT/-G genotyping may have an important impact on the management of both African American and Caucasian patients with chronic hepatitis C. Altogether, the identification of this TT/-G functional variant provides a new step in understanding the role of IL28B polymorphisms in the prediction of the response to chronic hepatitis C treatment.

MATERIALS AND METHODS
=====================

### Study patients.

Patients were included from the Swiss Hepatitis C Cohort Study (SCCS), a multicenter study of \>3,700 HCV-infected patients enrolled at eight major Swiss hospitals and their local affiliated centers since 2001 ([@bib17]; [@bib3]). Caucasian patients enrolled in the SCCS before August 1, 2010, with available DNA and written consent for genetic studies were selected. The study included patients with spontaneous HCV clearance (defined as presence of anti-HCV but undetectable HCV RNA without previous antiviral treatment) and those who had chronic infection with HCV genotypes 1, 2, 3, or 4 and were assessable for response to therapy with pegylated-IFN-α and ribavirin, i.e., who received \>80% of the recommended dose of each drug. Demographic characteristics including age, sex, HCV risk factors, HCV genotypes, alcohol consumption, markers of chronic infection with the hepatitis B virus and HIV, HCV viral load, liver biopsy data, and HCV treatment were extracted from clinical databases. SVR was defined as an undetectable HCV RNA in serum more than 24 wk after treatment termination. Severe fibrosis was considered in patients with a METAVIR score F3 or higher.

### SNP genotyping.

TT/-G *and rs12979860* were extracted from a GWAS-generated dataset ([@bib20]) or genotyped by TaqMan (Applied Biosystems), using the ABI 7500 Fast real time thermocycler, according to manufacturer's protocols. For TT/-G and *rs12979860*, TT and C were defined as WT and -G and T as mutant alleles, respectively. TaqMan probes and primers were designed and synthesized using Applied Biosystems software ([Table S3](http://www.jem.org/cgi/content/full/jem.20130012/DC1){#supp3}). Automated allele calling was performed using SDS software (Applied Biosystems). For quality control, all samples were also genotyped in an independent laboratory (KBioscience, Unit 7, Maple Park, Hoddesdon, Herts, UK) using KASP SNP genotyping system, a competitive allele-specific PCR incorporating a FRET quencher cassette. Patients with at least one missing genotype and/or discordant results regarding one polymorphism were excluded from the analyses.

### Statistical analysis.

Statistical analyses were performed using Stata (version 11.1, StataCorp LP). LD and Hardy-Weinberg equilibrium test were assessed using the programs pwld and genhw, respectively, both implemented in Stata. Strong LD was defined as an R^2^ \> 0.7. The association of *IL28B* polymorphisms with response to treatment and spontaneous clearance was performed by univariate and multivariate logistic regression. Age, duration of infection, and body mass index (BMI) were treated as continuous variables. Multiple logistic regression models were adjusted for age, sex, HCV RNA level, fibrosis stage, and, whenever appropriate, viral genotype. For *IL28B* SNPs, comparisons were made using an additive model (considering a similar effect for each additional copy of the minor allele), a neutral model (comparing separately patients with heterozygous and homozygous mutant genotypes to patients with WT genotypes), and, when appropriate, a recessive model (comparing patients with homozygous mutant genotypes to the others). Discrimination ability between two different logistic regression models was compared using the integrated discrimination improvement test (IDI) implemented in Stata ([@bib15]).

### PBMCs isolation and RT-PCR analysis.

PBMCs were prepared from 1.6 mg/ml of fresh EDTA blood from nine patients and six healthy donors with written consent and approval of Ethics committee. In brief, whole blood diluted in PBS was overlaid above Ficoll-Paque Plus (GE Healthcare) and mononuclear cells extracted by gradient density centrifugation. Viability, determined by trypan blue exclusion, was \>90%. PBMCs were stimulated with 50 µg/ml poly(I:C) and 0.1 µg/ml LPS for 4 or 8 h. Total RNA was isolated from PBMCs using an RNeasy Mini kit and the automated QIAcube (QIAGEN). 250 ng of total RNA was reverse transcribed using the QuantiTect Reverse Transcription kit (QIAGEN). The relative levels of IL28B, IP-10, and TNF transcripts were determined by RT-PCR, with a 7500 Fast real-time PCR system (Applied Biosystems), using the Power SYBR green PCR master mix (Applied Biosystems) with primers described in Table S3. Primers were designed using the Primer 3 software and validated by BLAST analysis. The relative levels of mRNA expression to HPRT were determined by the 2^(−ΔΔCt)^ method and expressed in arbitrary units. HPRT expression was not influenced by cell stimulation. The PCR products were run on a 2% agarose gel, purified (QIAquick Gel extraction kit; QIAGEN), cloned into a pGEM-T Easy vector (Promega), and sequenced on an ABI3130XL Sequencer (Applied Biosystems).

### Methylation analysis by bisulfite sequencing.

The TT/-G--containing region was amplified by PCR using primers detailed in Table S3. Regular sequencing was performed in eight patients (four homozygous for the WT C allele and four homozygous for the mutant T *rs12979860* allele). Polymorphic region was also sequenced after bisulfite treatment of DNA, with a subsequent cloning step, in 26 additional patients (13 homozygous for the WT C allele and 13 homozygous for the mutant T *rs12979860* allele). Specifically, 250 ng of genomic DNA were treated with sodium bisulfite using the EpiTect Bisulfite kit (QIAGEN) per manufacturer's recommendations and the polymorphic TT/-G region was amplified using bisulfite sequencing primers designed using MethPrimer (<http://www.urogene.org/methprimer/index1.html>). PCR amplifications from 10 ng of DNA consisted of an initial activation of HotStartTaq DNA polymerase (QIAGEN) at 95°C for 15 min, followed by 40 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 1 min, and 1 cycle at 72°C for 10 min. Amplicons were gel purified with the QIAquick Gel Extraction kit (QIAGEN) and cloned into a pGEM-T Easy vector (Promega). Five clones from each sample were sequenced using an ABI BigDye Terminator v.3.0 Cycle sequencing kit (Applied Biosystems) and an ABI3130XL Sequencer (Applied Biosystems).

### Online supplemental material.

Table S1 shows patient characteristics. Table S2 shows genotypic association of *IL28B* polymorphisms with response to pegylated IFN-α and ribavirin in chronically infected HCV patients. Table S3 shows primers. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20130012/DC1>.
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